RINVOQ (Abbvie Pty Ltd)
Product name
RINVOQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
189 (255 working days)
Active ingredients
upadacitinib hemihydrate
Registration type
EOI
Indication
Crohn’s Disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease, who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biological medicine.